Related Experiment Video

Updated: Aug 21, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

KRAS inhibitors: going noncovalent

Matthias Drosten1, Mariano Barbacid2

  • 1Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC-USAL, Salamanca, Spain.

Molecular Oncology
|November 16, 2022
PubMed

Insights

Researchers developed MRTX1133, a novel noncovalent inhibitor targeting the KRAS G12D mutation common in pancreatic and colorectal cancers. This drug demonstrated significant antitumor effects in preclinical models, offering new therapeutic possibilities.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS G12D mutations are prevalent in pancreatic and colorectal cancers, driving tumor growth.
  • Targeting KRAS mutations is a key strategy in cancer therapy.

Purpose of the Study:

  • To identify and validate a novel, potent, selective, and noncovalent inhibitor for KRAS G12D.
  • To evaluate the antitumor activity of MRTX1133 in preclinical cancer models.

Main Methods:

  • Structure-based drug design informed by KRAS G12C inhibitor adagrasib.
  • In vitro and in vivo testing of MRTX1133 in pancreatic and colorectal cancer models.
  • Combination studies with cetuximab (anti-EGFR) and BYL-719 (PI3Kα inhibitor).

Main Results:

  • Identification and validation of MRTX1133, a potent and selective noncovalent KRAS G12D inhibitor.
  • MRTX1133 inhibited both inactive and active states of KRAS G12D.
  • Significant antitumor activity observed in preclinical models, enhanced by combination therapies.

Conclusions:

  • MRTX1133 represents a promising therapeutic candidate for KRAS G12D-driven cancers.
  • Combination strategies involving MRTX1133 may enhance treatment efficacy.
Keywords:
KRASG12Dcolorectal cancercombination therapiesnoncovalent bindingpancreatic ductal adenocarcinoma

More Related Videos

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

653
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

542

Related Concept Videos

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.1K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.2K